Cytek Biosciences prelim FY2023 revenue near high end of $188M-$192M guidance

Cytek Biosciences, Inc.

2023-FY EPS reported -$0.09 revenue$193,015,000

Preliminary full-year 2023 revenue expected near high end of prior guidance range of $188M-$192M.
Final Q4 and FY2023 results and 2024 guidance to be reported on expected earnings call in late February 2024.
CEO Wenbin Jiang to present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytek Biosciences, Inc. reported preliminary financial results for the full year ended December 31, 2023.

Period: the full year ended December 31, 2023
Result: preliminary results

Exact text from the filing

Cytek expects its full year revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million

View on SEC.gov

Browse all earnings releases →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-004805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.